Deals Of The Week Keeps Tabs As Tax Trimming Fuels Deal-Making
Executive Summary
As more biopharmaceutical companies become profitable and global, tax strategy becomes an increasingly important aspect of deal-making and intellectual property management. Deals of the Week looks at recent tax winners, new tax tactics and potential deal targets that are attractive in part because of their high – or low – tax rates.
You may also be interested in...
Tax Benefits, Branded Portfolio, Synergies Drive Actavis’ Acquisition of Warner Chilcott
Actavis’ purchase of Warner Chilcott will lower the former’s overall tax rate significantly, expand its specialty pharma business to 25% of total revenues, and provide global critical mass – all necessary responses to a future that includes fewer opportunities for small molecule generics and greater pricing pressures.
Merck/Ariad’s Hopes For Ridaforolimus May Rest Beyond Sarcoma After FDA Rejection
In a “complete response” letter, the agency said it wanted more clinical data on use of the mTOR inhibitor as a maintenance therapy in metastatic soft tissue or bone sarcoma. Merck says it is confident in ridaforolimus’ potential and points to an active development program in various solid tissue cancers.
Roche Pharma CEO Graham On Growth Prospects, Policy Pressures, Alzheimer’s And More
“I don’t think anybody can afford to not be in the Alzheimer’s race,” Graham said in one of her first public appearances since becoming CEO of Roche pharmaceuticals.